Dry Age Related Macular Degeneration (AMD) Study

Official Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration


The purpose of this study is to determine the safety and efficacy of Lampalizumab in the treatment of geographic atrophy secondary to age related macular edema (also known as dry AMD).

Eligibility criteria:

- Ages 50 and older
- Geographic Atrophy Secondary to Age Related Macular Degeneration

Contact Information

Kimberly Rickard